Gaetano M. Guglielmino's departure as Chief Commercial Officer of Treace Medical Concepts, Inc. was reported, effective April 8, 2026; the filing names no successor. As of November 6, 2026, Treace Medical Concepts, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 9, 2026, naming 1 appointment and 1 departure (Form 8-K, April 9, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Treace Medical Concepts, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Treace Medical Concepts, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-09. It names 1 person, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Treace Medical Concepts, Inc. files it.
Also on the record for Treace Medical Concepts, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.79% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by John T. Treace | 19.2% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.85% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 5.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Neil Gagnon | 9.6% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.8% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 5.8% of the class | 5%+ stakes | Source |
| August 15, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.91% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Treace Medical Concepts, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Treace Medical Concepts, Inc. and the records around it.
Treace Medical Concepts, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Gagnon Securities LLC also filed stake reports on 4 other companies: CNFinance Holdings Ltd. (Nov 2026), Ameresco, Inc. (Aug 2026), Kaltura, Inc. (Aug 2026)
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC also filed stake reports on 21 other companies: Baldwin Insurance Group, Inc. (Nov 2026), GeneDx Holdings Corp. (Nov 2026), i3 Verticals, Inc. (Aug 2026)
- BANK OF AMERICA CORP /DE/ also filed stake reports on 74 other companies: BlackRock 2037 Municipal Target Term Trust (Nov 2026), TRIMAS CORP (Nov 2026), PIMCO CALIFORNIA MUNICIPAL INCOME FUND (Nov 2026)
Watch Treace Medical Concepts, Inc.
Get an email when Treace Medical Concepts, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Treace Medical Concepts, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Treace Medical Concepts, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Treace Medical Concepts, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-09 | Out | Chief Commercial Officer | 2026-04-08 | 8-K, 2026-04-09 | |
| 2026-04-09 | In | 2026-04-09 | 8-K, 2026-04-09 |
Who leads Treace Medical Concepts, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Commercial Officer: Gaetano M. Guglielmino, departure reported, effective 2026-04-08 (filed 2026-04-09). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Treace Medical Concepts, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Commercial Officer at Treace Medical Concepts, Inc., with the record behind each one.
Find candidates like Chief Commercial Officer at Treace Medical Concepts, Inc.Every change, in the filing's words
Departing: Gaetano M. Guglielmino, Chief Commercial Officer, effective 2026-04-08
Effective as of the close of business on April 8, 2026, Gaetano M. Guglielmino, Chief Commercial Officer of Treace Medical Concepts, Inc. (the "Company"), will depart from the Company.
Appointed: Gaetano M. Guglielmino, effective 2026-04-09
In order to assist with the transition of his responsibilities, Mr. Guglielmino entered into a Consulting Services Agreement with the Company, effective as of April 9, 2026, that provides, among other things, that Mr. Guglielmino will serve as an independent consultant to the Company through January 31, 2027.
- The Company does not plan to fill the Chief Commercial Officer role.
- Instead, Mr. Guglielmino's responsibilities will be assumed by existing employees, and the Senior Vice President, Sales will now report directly to the Chief Executive Officer, John T. Treace.
- Mr. Guglielmino's departure from the Company is not the result of any dispute or disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Mr. Guglielmino also signed a release of claims in favor of the Company and a written attestation that his confidentiality, nonsolicitation and noncompetition agreement is in effect and enforceable.
Tools for this story
Each opens in a new tab, filled in for Treace Medical Concepts, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.